Results from a new analysis of the Phase III RELAX-AHF study published in the European Heart Journal and presented as...
Novartis announced results from the global Phase III RELAX-AHF-2 study investigating the efficacy, safety and tolerability of RLX 030 (serelaxin)...
Results from the phase III RELAX-AHF-2 trial of Reasanz (serelaxin), from Novartis, for the treatment of patients with acute heart...
Phase III study results show that investigational RLX030 (serelaxin) reduced all-cause mortality in patients with Acute Heart Failure (AHF). The...
RLX 030 (serelaxin), from Novartis, may be more effective for relieving Dyspnea in Heart Failure with preserved ejection fraction (HFpEF)...
RELAX-AF was a randomized, double-blind study involving 1,161 patients and was designed to compare the efficacy and safety profile of...
Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion for the use...
Novartis announced that the FDA has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RLX...
Several clinical conditions may precipitate acute heart failure (AHF) and influence clinical outcome. In this study we hypothesized that precipitating factors are independently associated with 90-day risk of death in AHF.
The European Commission has approved Entresto (sacubitril/valsartan), from Novartis, for the treatment of adult patients with symptomatic chronic heart failure...